Health advocacy organizations and the pharmaceutical industry

an analysis of disclosure practices.

Sheila M. Rothman, Victoria Raveis, Anne Friedman, David J. Rothman

Research output: Contribution to journalArticle

Abstract

Health advocacy organizations (HAOs) are influential stakeholders in health policy. Although their advocacy tends to closely correspond with the pharmaceutical industry's marketing aims, the financial relationships between HAOs and the pharmaceutical industry have rarely been analyzed. We used Eli Lilly and Company's grant registry to examine its grant-giving policies. We also examined HAO Web sites to determine their grant-disclosure patterns. Only 25% of HAOs that received Lilly grants acknowledged Lilly's contributions on their Web sites, and only 10% acknowledged Lilly as a grant event sponsor. No HAO disclosed the exact amount of a Lilly grant. As highly trusted organizations, HAOs should disclose all corporate grants, including the purpose and the amount. Absent this disclosure, legislators, regulators, and the public cannot evaluate possible conflicts of interest or biases in HAO advocacy.

Original languageEnglish (US)
Pages (from-to)602-609
Number of pages8
JournalAmerican Journal of Public Health
Volume101
Issue number4
DOIs
StatePublished - Apr 1 2011

Fingerprint

Disclosure
Drug Industry
Organized Financing
Organizations
Health
Conflict of Interest
Health Policy
Marketing
Registries

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Health advocacy organizations and the pharmaceutical industry : an analysis of disclosure practices. / Rothman, Sheila M.; Raveis, Victoria; Friedman, Anne; Rothman, David J.

In: American Journal of Public Health, Vol. 101, No. 4, 01.04.2011, p. 602-609.

Research output: Contribution to journalArticle

@article{4695fe29b27c438aa7f3a1db1256821d,
title = "Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices.",
abstract = "Health advocacy organizations (HAOs) are influential stakeholders in health policy. Although their advocacy tends to closely correspond with the pharmaceutical industry's marketing aims, the financial relationships between HAOs and the pharmaceutical industry have rarely been analyzed. We used Eli Lilly and Company's grant registry to examine its grant-giving policies. We also examined HAO Web sites to determine their grant-disclosure patterns. Only 25{\%} of HAOs that received Lilly grants acknowledged Lilly's contributions on their Web sites, and only 10{\%} acknowledged Lilly as a grant event sponsor. No HAO disclosed the exact amount of a Lilly grant. As highly trusted organizations, HAOs should disclose all corporate grants, including the purpose and the amount. Absent this disclosure, legislators, regulators, and the public cannot evaluate possible conflicts of interest or biases in HAO advocacy.",
author = "Rothman, {Sheila M.} and Victoria Raveis and Anne Friedman and Rothman, {David J.}",
year = "2011",
month = "4",
day = "1",
doi = "10.2105/AJPH.2010.300027",
language = "English (US)",
volume = "101",
pages = "602--609",
journal = "American Journal of Public Health",
issn = "0090-0036",
publisher = "American Public Health Association Inc.",
number = "4",

}

TY - JOUR

T1 - Health advocacy organizations and the pharmaceutical industry

T2 - an analysis of disclosure practices.

AU - Rothman, Sheila M.

AU - Raveis, Victoria

AU - Friedman, Anne

AU - Rothman, David J.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Health advocacy organizations (HAOs) are influential stakeholders in health policy. Although their advocacy tends to closely correspond with the pharmaceutical industry's marketing aims, the financial relationships between HAOs and the pharmaceutical industry have rarely been analyzed. We used Eli Lilly and Company's grant registry to examine its grant-giving policies. We also examined HAO Web sites to determine their grant-disclosure patterns. Only 25% of HAOs that received Lilly grants acknowledged Lilly's contributions on their Web sites, and only 10% acknowledged Lilly as a grant event sponsor. No HAO disclosed the exact amount of a Lilly grant. As highly trusted organizations, HAOs should disclose all corporate grants, including the purpose and the amount. Absent this disclosure, legislators, regulators, and the public cannot evaluate possible conflicts of interest or biases in HAO advocacy.

AB - Health advocacy organizations (HAOs) are influential stakeholders in health policy. Although their advocacy tends to closely correspond with the pharmaceutical industry's marketing aims, the financial relationships between HAOs and the pharmaceutical industry have rarely been analyzed. We used Eli Lilly and Company's grant registry to examine its grant-giving policies. We also examined HAO Web sites to determine their grant-disclosure patterns. Only 25% of HAOs that received Lilly grants acknowledged Lilly's contributions on their Web sites, and only 10% acknowledged Lilly as a grant event sponsor. No HAO disclosed the exact amount of a Lilly grant. As highly trusted organizations, HAOs should disclose all corporate grants, including the purpose and the amount. Absent this disclosure, legislators, regulators, and the public cannot evaluate possible conflicts of interest or biases in HAO advocacy.

UR - http://www.scopus.com/inward/record.url?scp=79955666819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955666819&partnerID=8YFLogxK

U2 - 10.2105/AJPH.2010.300027

DO - 10.2105/AJPH.2010.300027

M3 - Article

VL - 101

SP - 602

EP - 609

JO - American Journal of Public Health

JF - American Journal of Public Health

SN - 0090-0036

IS - 4

ER -